Side effects of certain medication can put people at high risk for harm, increasing pain, and long-term medical conditions. It is the responsibility of drug manufacturers to make publicly known the severity of side effects its products may cause.
According to Science Daily, “hundreds of thousands of hip and knee replacement surgeries are performed in the United States each year.” While these procedures are generally very effective at reducing pain and restoring mobility, there is a high rate of failure of these devices. There is such a high rate of failure, in fact, that Dr.
Abbott Diabetes Care, a lead developer and manufacturer of glucose monitoring and testing systems and strips has announced that it is issuing a voluntary recall of certain lots of its FreeStyle and FreeStyle Lite Blood Glucose Testing Strips in the United States. The defective medical device recall was issued on November 27, 2013 after the company found that approximately 20 lots of the test strips may return erroneously low blood glucose readings when used with certain types of FreeStyle blood glucose meters.
Two products extremely popular for use in dialysis treatments, NaturaLyte and GranuFlo, were created by Fresenius Medical Care Holdings. These products have been named in numerous lawsuits recently, since there are side effects that can lead to serious medical problems and conditions for patients getting dialysis treatment. If you have been the victim of a defective medical device or medical malpractice, you need to speak with a personal injury attorney.
At the end of January, according to beforeitsnews.com, Johnson & Johnson was facing a slew of claims regarding a hip replacement the company developed “that had several design defects.” The hip replacement, manufactured by Johnson & Johnson subsidiary DePuy Orthopedics, is suspected to have leaked toxic debris into patients’ bloodstreams.
In 2012, the Food and Drug Administration (FDA) passed a new act, the Medical Device User Fee Amendments, which went into effect on October 1. The new act, according to the FDA, “includes performance goals and user fees paid to the FDA by medical device companies when they register and list with the FDA and when they submit an application to market a medical device in the U.S.” In the long run, the new act will help to shape with way that the FDA approves products, clinical trials, and also shorten timelines for scheduling appeals of meetings or decisions.
Researchers that are from the Cincinnati Children’s Hospital Medical Center have studied children that either have a pacemaker (40 patients) or an implanted defibrillator (133 patients). The researchers have been assessing the patients’ quality of life compared to other children that have congenital heart disease and children that are healthy.